Selective inhibition of leukemic cell proliferation by bcr-abl a

Details Selective inhibition of leukemic cell proliferation by bcr-abl a Selective inhibition of leukemic cell proliferation by bcr-abl a

1993-11-15

1997-07-29

Chambers, Jasemine C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 245, 4351723, 435375, 935 62, A61K 4800, C07H 2104, C12N 1500, C12N 500

Patent

active

056522223

ABSTRACT:
Leukemias characterized by the presence of the Philadelphia chromosome and the expression of the hybrid bcr-abl gene are treated with antisense oligonucleotides complementary to a target sequence of the bcr-abl mRNA transcript including the breakpoint junction. Individual chronic myelogoneous leukemia patients or Philadelphia chromosome-positive acute lymphocytic leukemia patients are treated by first sequencing the individual's bcr-abl breakpoint junction, and then administering antisense oligonucleotides complementary thereto. The oligonucleotides are designed to hybridize specifically to the bcr-abl breakpoint junction without substantial cross hybridization to untranslocated c-abl sequences. Treatment may comprise in vivo administration of antisense oligonucleotides, or ex vivo treatment such as bone marrow purging.

REFERENCES:
patent: 4681840 (1987-07-01), Stephenson et al.
patent: 4857466 (1989-08-01), Saunders et al.
patent: 4874853 (1989-10-01), Rossi
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
Kawasaki et al (1988) Proced. Natl. Acad. Sci. 85, 5698-5702.
Harrison's Principles of Internal Medicine, vol. 2, 1994, pp. 1757-1764.
Tseng et al (1994) Cancer Gene Therapy 1, 65-71.
deFabritis et al (1995) Leukemia 9, 662-664.
Daley et al., Science 247, 824-830 (1990).
Heisterkamp et al., Nature 344, 251-253 (1990).
Caracciolo et al., Science 245, 1107-1110 (1989).
Kawasaki et al., Proc. Natl. Acad. Sci. USA 85, 5698-5702 (1988).
Yuan et al., Clin Res. 39, (2) (abs. 211A) (Apr. 19, 1991).
Yuan et al., J. Cellular Biochem., Supp. 15D, 37 (Feb. 2, 1991).
Han et al. Proc. Natl. Acad. Sci. 88, 4313-4317 (1991).
Anfossi et al., Proc. Natl. Acad. Sci. 86, 3379-3383 (1989).
Kitajima et al., Science 258, 1792-1795 (1992).
Levy, "Interferon and Interferon Inducers", Marcel Dekker, Inc., New York and Basel, 167-185 (1980).
Madaio et al, The J. of Immunology, 137, 2535-2540 No. 8 (1986).
Majello et al., Proc. Natl. Acad. Sci. USA 83, 9636-9640 (1986).
Gewirtz et al., Science 242, Reports: 1303-1306 (1988).
Gewirtz et al., Science 245, Reports: 180-183 (1989).

Affiliated with

Also associated with

Rating

Selective inhibition of leukemic cell proliferation by bcr-abl a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective inhibition of leukemic cell proliferation by bcr-abl a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective inhibition of leukemic cell proliferation by bcr-abl a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-633765